DPYD Promoter Hypermethylation and 5-FU Toxicity
Author Information
Author(s): Ursula Amstutz, Simone Farese, Stefan Aebi, Carlo R Largiadèr
Primary Institution: Inselspital, Bern University Hospital, and University of Bern
Hypothesis
Is hypermethylation of the DPYD promoter region a major predictor of severe toxicity in 5-fluorouracil based chemotherapy?
Conclusion
DPYD promoter hypermethylation is not a major prognostic factor for severe toxicity in 5-FU based chemotherapy.
Supporting Evidence
- No evidence of DPYD promoter methylation was observed in any of the investigated patient samples.
- Control experiments could detect as little as 10% methylated genomic DNA.
Takeaway
The study looked at whether a specific change in a gene's control region could explain why some cancer patients get very sick from a common chemotherapy drug, but found no evidence that it does.
Methodology
The methylation status of the DPYD promoter region was evaluated in 27 cancer patients receiving 5-FU based chemotherapy, comparing those with severe toxic side effects to control patients.
Limitations
The study only included a small sample size and focused on a specific epigenetic marker.
Participant Demographics
Patients included 17 with severe toxicity and 10 control patients, all suffering from solid malignant tumors.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website